Adapted from Finn RS, et al. 2016.2
Data cut-off date: February 26, 2016.
*Defined as confirmed complete response or partial response.2 †Defined as confirmed complete response, partial response, or stable disease for ≥24 weeks.2
CBR = clinical benefit rate; HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; ITT = intention-to-treat; LET = letrozole; N/n = number of patients; ORR = objective response rate; PLA = placebo.
HR = hormone receptor; HER2 = human epidermal growth factor receptor 2; mPFS = median progression-free survival.
© 2021 Pfizer Pte Ltd. All rights reserved.
The information provided in this site is intended only for Health Care Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Corporation Singapore Limited is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.